Abbvie Presents Data Showing RINVOQ Met Its Primary Endpoint

- In SELECT-AXIS 1, RINVOQ™ (upadacitinib; 15 mg, once-daily) achieved the primary endpoint of ASAS40 response in adult patients with active ankylosing spondylitis (AS) at 14 weeks versus placebo[1] - Full results

Benzinga · 11/12/2019 16:17

- In SELECT-AXIS 1, RINVOQ™ (upadacitinib; 15 mg, once-daily) achieved the primary endpoint of ASAS40 response in adult patients with active ankylosing spondylitis (AS) at 14 weeks versus placebo[1]
- Full results were presented today at the 2019 ACR/ARP Annual Meeting in Atlanta
- The safety profile was consistent with that of previous studies across indications, with no new safety risks detected[1,2]
- Affecting more than five million people worldwide, AS is a chronic inflammatory disease that causes pain and stiffness in the joints, mainly in the spine[3,4]

NORTH CHICAGO, Ill., Nov. 12, 2019 /PRNewswire/ -- AbbVie (NYSE:ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2/3 SELECT-AXIS 1 trial in which twice as many adult patients with active ankylosing spondylitis (AS) treated with RINVOQ™ (upadacitinib; 15 mg, once-daily) achieved the primary endpoint of Assessment of SpondyloArthritis International Society (ASAS) 40 response at week 14 versus placebo (52 percent vs. 26 percent; p<0.001).1 SELECT-AXIS 1 is the first trial to evaluate the efficacy and safety of RINVOQ in adult patients with active AS who are naïve to biologic disease-modifying antirheumatic drugs (bDMARDs) and had inadequate response or intolerance to nonsteroidal anti-inflammatory drugs (NSAIDs).1